Erste Group Bank Brokers Lower Earnings Estimates for Amgen

Amgen Inc. (NASDAQ:AMGN) – Equities research analysts at Erste Group Bank reduced their FY2026 earnings per share estimates for shares of Amgen in a research report issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now anticipates that the medical research company will post earnings per share of $22.41 for the year, down from their prior estimate of $22.45. Erste Group Bank has a “Hold” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $22.31 per share.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS.

Several other brokerages have also recently commented on AMGN. Mizuho boosted their price target on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 16th. UBS Group raised their price objective on shares of Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Argus lowered their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Daiwa Securities Group dropped their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Finally, Truist Financial increased their target price on shares of Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research note on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $356.62.

Amgen Stock Performance

Shares of AMGN stock opened at $366.29 on Monday. The stock has a 50-day simple moving average of $347.69 and a 200 day simple moving average of $350.53. The stock has a market capitalization of $197.69 billion, a P/E ratio of 25.49, a P/E/G ratio of 3.71 and a beta of 0.41. Amgen has a fifty-two week low of $269.77 and a fifty-two week high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amgen

A number of institutional investors have recently bought and sold shares of AMGN. Processus Wealth & Capital Management LLC raised its holdings in Amgen by 2.6% during the 2nd quarter. Processus Wealth & Capital Management LLC now owns 11,001 shares of the medical research company’s stock worth $3,984,000 after buying an additional 279 shares during the period. Regent Peak Wealth Advisors LLC boosted its holdings in shares of Amgen by 2.2% in the second quarter. Regent Peak Wealth Advisors LLC now owns 1,729 shares of the medical research company’s stock worth $626,000 after buying an additional 37 shares during the period. Hudson Value Partners LLC boosted its holdings in shares of Amgen by 4.2% in the second quarter. Hudson Value Partners LLC now owns 21,171 shares of the medical research company’s stock worth $7,667,000 after buying an additional 849 shares during the period. Tema ETFs LLC increased its position in shares of Amgen by 14.5% in the second quarter. Tema ETFs LLC now owns 26,231 shares of the medical research company’s stock worth $9,499,000 after acquiring an additional 3,326 shares in the last quarter. Finally, West Branch Capital LLC increased its position in shares of Amgen by 8.3% in the second quarter. West Branch Capital LLC now owns 1,167 shares of the medical research company’s stock worth $423,000 after acquiring an additional 89 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen advanced its obesity pipeline with fresh Phase 1 data on AMG 133 injection formats, which could support long-term growth if the program continues to show promise. Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
• Positive Sentiment: Amgen’s stock was highlighted in market coverage as teasing a buy point, suggesting technical traders may see room for upside if broader market conditions stabilize. Stock Market Today: Dow Sees Red While Amgen Shares Tease A Buy Point (Live Coverage)
• Neutral Sentiment: Amgen remains a candidate for another earnings beat, according to recent coverage pointing to its history of topping estimates and solid fundamentals. Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Amgen to $23.58 from $23.62 and kept a Hold rating, a modest negative for sentiment but not a major change in the outlook. Amgen Inc. (NASDAQ:AMGN) Free Report
• Negative Sentiment: Amgen halted a late-stage bemarituzumab gastric cancer trial, adding uncertainty to part of its oncology pipeline and pressuring investor expectations. Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations
• Negative Sentiment: Amgen also terminated a key Phase 3 rocatinlimab eczema study, another setback that may raise concerns about the durability of its pipeline growth. Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.